<DOC>
	<DOCNO>NCT02020135</DOCNO>
	<brief_summary>PSMA ADC 2301EXT open-label study assess anti-tumor activity measure radiographic image biomarkers , safety tolerability Prostate Specific Membrane Antigen Antibody Drug Conjugate ( PSMA ADC ) subject mCRPC . Subjects participate PSMA ADC 2301 study , opinion Principal Investigator likely benefit continue treatment PSMA ADC eligible PSMA ADC 2301 extension study . Subjects benefit treatment may able receive additional eight sixteen dos ( every 3 week ) PSMA ADC .</brief_summary>
	<brief_title>An Open-label Extension Study PSMA ADC 2301 mCRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects complete PSMA ADC 2301 study , opinion investigator , likely benefit continue treatment PSMA ADC 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 3 . If chemically castrate , subject must agree stay androgendeprivation therapy duration study 4 . If applicable , men must agree commit use medically acceptable method birth control ( e.g. , spermicide conjunction barrier condom ) sexual abstinence duration study , include 30 day last dose study drug 1 . An acute infection require ongoing antibiotic therapy ( e.g. , UTI , indwell catheter potential site ( ) infection ) 2 . History significant hypersensitivity reaction PSMA ADC component , prior investigational approve monoclonal antibody ( mAbs ) , immunoglobulin ( Ig ) fusion protein ( e.g. , circulate neutralize antibody ) , ADC 3 . Clinically significant cardiac disease severe debilitate pulmonary disease 4 . Any recent ongoing medical condition may interfere subject 's participation compliance study evaluation PSMA ADC</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>